Chris Odgen
The Royal Marsden NHS Foundation Trust
3 Papers
Chris Odgen is an academic researcher from The Royal Marsden NHS Foundation Trust. The author has contributed to research in topics: Prostate cancer & Internal medicine. The author has an hindex of 2, co-authored 3 publications.
Chat about Author
Papers
Prostate Specific Antigen Criteria to Diagnose Failure of Cancer Control following Focal Therapy of Nonmetastatic Prostate Cancer Using High Intensity Focused Ultrasound.
Philipp M. Huber,Naveed Afzal,Manit Arya,Manit Arya,Manit Arya,Silvan Boxler,Tim Dudderidge,Mark Emberton,Mark Emberton,Stephanie Guillaumier,Stephanie Guillaumier,Richard Hindley,Feargus Hosking-Jervis,Feargus Hosking-Jervis,Lucas Leemann,Henry Lewi,Neil McCartan,Neil McCartan,Caroline M. Moore,Caroline M. Moore,Raj Nigam,Chris Odgen,Raj Persad,George N. Thalmann,Jaspal Virdi,Mathias Winkler,Hashim U. Ahmed,Hashim U. Ahmed,Hashim U. Ahmed +28 more
TL;DR: In this article, the authors determined whether prostate specific antigen criteria after focal high intensity focused ultrasound to treat prostate cancer could diagnose treatment failure, based on a set of criteria that included prostate specific antigens.
43
Focal HIFU therapy for anterior compared to posterior prostate cancer lesions.
Philipp M. Huber,Naveed Afzal,Manit Arya,Manit Arya,Manit Arya,Silvan Boxler,Tim Dudderidge,Mark Emberton,Mark Emberton,Stephanie Guillaumier,Stephanie Guillaumier,Richard Hindley,Feargus Hosking-Jervis,Lucas Leemann,Henry Lewi,Neil McCartan,Neil McCartan,Caroline M. Moore,Caroline M. Moore,Raj Nigam,Chris Odgen,Raj Persad,Jaspal Virdi,Mathias Winkler,Hashim U. Ahmed,Hashim U. Ahmed +25 more
TL;DR: Treating anterior prostate cancer lesions with focal HIFU may be less effective compared to posterior tumours.
An Exploratory Study of Dose Escalation vs Standard Focal High-Intensity Focused Ultrasound for Treating Nonmetastatic Prostate Cancer
Philipp M. Huber,Naveed Afzal,Manit Arya,Manit Arya,Manit Arya,Silvan Boxler,Tim Dudderidge,Mark Emberton,Mark Emberton,Stephanie Guillaumier,Stephanie Guillaumier,Richard Hindley,Feargus Hosking-Jervis,Feargus Hosking-Jervis,Lucas Leemann,Henry Lewi,Neil McCartan,Neil McCartan,Caroline M. Moore,Caroline M. Moore,Raj Nigam,Chris Odgen,Raj Persad,George N. Thalmann,Jaspal Virdi,Mathias Winkler,Hashim U. Ahmed,Hashim U. Ahmed,Hashim U. Ahmed +28 more
TL;DR: D dose escalation focal-HIFU may achieve higher rates of disease control compared to standard focal- HIFU and further prospective comparative studies are needed.